



Cover image: Change in the number of CD138+ plasma cells in representative serial synovial tissue samples obtained at 4 (A) and 16 (B) weeks after initiation of rituximab treatment. See p 917.

### Editor

Tore K Kvien

### Associate Editors

Francis Berenbaum  
Hans Bijlsma  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow

### Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 5.767

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2008 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission.

ARD is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Cambrian Printers Limited, Aberystwyth, UK.

*Annals of the Rheumatic Diseases* (USPS No: 002-152) is published monthly by BMJ Publishing Group and distributed in the USA by SPP, 75 Aberdeen Road, Emigsville, PA 17318, USA. Periodicals postage paid at Emigsville, PA, USA. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, PO Box 437, Emigsville, PA 17318-0437, USA.

## Editorial

- 905** Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside  
*M Cutolo, R H Straub, F Buttgerieit*

## Review

- 909** The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis  
*G Schett, J Zwerina, G Firestein*

## Extended reports

- 917** Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response  
*R M Thurlings, K Vos, C A Wijbrands, A H Zwinderman, D M Gerlag, P P Tak*

- 926** Magnetic resonance imaging can accurately assess the long-term progression of knee structural changes in experimental dog osteoarthritis  
*C Boileau, J Martel-Pelletier, F Abram, J-P Raynaud, É Troncy, M-A D'Anjou, M Moreau, J-P Pelletier*

- 933** The MHC2TA -168A/G polymorphism and risk for rheumatoid arthritis: a meta-analysis of 6861 patients and 9270 controls reveals no evidence for association  
*P G Bronson, L A Criswell, L F Barcellos*

- 937** Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response  
*S Oren, M Mandelboim, Y Braun-Moscovici, D Paran, J Ablin, I Litinsky, D Comanesther, D Levartovsky, E Mendelson, R Azar, I Wigler, A Balbir-Gurman, D Caspi, O Elkayam*

- 942** Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis  
*T K Kvien, E Fjeld, B Slatkowsky-Christensen, M Nichols, Y Zhang, A Proven, K Mikkelsen, Ø Palm, A A Borisy, J Lessem*

- 949** Exocrine function in primary Sjögren syndrome: natural course and prognostic factors  
*K Haldorsen, K Moen, H Jacobsen, R Jonsson, J G Brun*

- 955** Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review  
*N Zeboulon, M Dougados, L Gossec*

- 960** Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005  
*L Annemans, E Spaepen, M Gaskin, M Bonnemaire, V Malier, T Gilbert, G Nuki*

- 967** Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis  
*T Heiberg, T K Kvien, P Mowinckel, D Aletaha, J S Smolen, K B Hagen*

- 972** The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping  
*M Heckmann, J U Holle, L Arning, S Knaup, B Hellmich, M Nothnagel, P Jagiello, W L Gross, J T Epplen, S Wiczorek*

- 980** Association between radiographic severity of rheumatoid arthritis and shared epitope alleles: differing mechanisms of susceptibility and protection  
*D Mewar, I Marinou, A L Coote, D J Moore, M Akil, D Smillie, M C Dickson, M H Binks, D S Montgomery, A G Wilson*

- 984** Pregnancy induces numerical and functional changes of CD4+CD25<sup>high</sup> regulatory T cells in patients with rheumatoid arthritis  
*F Förger, N Marcoli, S Gadola, B Möller, P M Villiger, M Østensen*

- 991** Autologous non-myceloablative haematopoietic stem cell transplantation for refractory systemic vasculitis  
*L Statkute, Y Oyama, W G Barr, R Sufit, S Ho, L Verda, Y Loh, K Young, K Quigley, R K Burt*

- 998** Detection of rheumatoid arthritis bone erosions by two different dedicated extremity MRI units and conventional radiography  
*A Duer-Jensen, A Vestergaard, U M Dohn, B Ejbjerg, M L Hetland, E Albrecht-Beste, M Østergaard*

- 1004** Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force  
*C Mukhtyar, O Flossmann, B Hellmich, P Bacon, M Cid, J W Cohen-Tervaert, W L Gross, L Guillemin, D Jayne, A Mahr, P A Merkel, H Raspe, D Scott, J Witter, H Yazici, R A Luqmani, on behalf of the European Vasculitis Study Group (EUVAS)*

- 1011** B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response  
*G Cambridge, D A Isenberg, J C W Edwards, M J Leandro, T-S Migone, M Teodorescu, W Stohl*

- 1017** Recommendations for the content and conduct of European League Against Rheumatism (EULAR) musculoskeletal ultrasound courses  
*E Naredo, J W J Bijlsma, P G Conaghan, C Acebes, P Balint, H Berner-Hammer, G A W Bruyn, P Collado, M A D'Agostino, J J de Agustin, E de Miguel, E Filippucci, W Grassi, A Iagnocco, D Kane, J M Koski, B Manger, L Mayordomo, I Möller, C Moragues, E Rejón, M Szkudlarek, L Terslev, J Usón, R J Wakefield, W A Schmidt*

### MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>



COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

[www.publicationethics.org.uk](http://www.publicationethics.org.uk)

**Concise reports**

- 1023** Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry  
*M L Hetland, H M Lindegaard, A Hansen, J Podenphant, J Unkerskov, V S Ringsdal, M Østergaard, U Tarp, on behalf of all departments of rheumatology in Denmark*
- 1027** Anti-PDGFR- $\alpha$  antibodies measured by non-bioactivity assays are not specific for systemic sclerosis  
*E Balada, C P Simeón-Aznar, J Ordi-Ros, M Rosa-Leyva, A Selva-O'Callaghan, J Pardos-Gea, V Fonollosa-Pla, M Vilardell-Tarrés*
- 1030** MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis  
*M Both, K Ahmadi-Simab, M Reuter, O Dourvos, E Fritzer, S Ullrich, W L Gross, M Heller, M Bähre*
- 1034** Differences in descriptions of Kellgren and Lawrence grades of knee osteoarthritis  
*D Schipphof, M Boers, S M A Bierma-Zeinstra*
- 1037** Clinical significance of increased CD4<sup>+</sup>CD25<sup>-</sup>Foxp3<sup>+</sup> T cells in patients with new-onset systemic lupus erythematosus  
*B Zhang, X Zhang, F L Tang, L P Zhu, Y Liu, P E Lipsky*
- 1041** Ethical and legal constraints on data sharing between countries in multinational epidemiological studies in Europe report from a joint workshop of the European League Against Rheumatism standing committee on epidemiology with the "AutoCure" project  
*A Zink, A J Silman*
- 1044** Delayed lupus nephritis  
*D-C Varela, G Quintana, E C Somers, A Rojas-Villarraga, G Espinosa, M-E Hincapie, W J McCune, R Cervera, J-M Anaya*
- 1049** Survey on management of gout among Dutch rheumatologists  
*M K Reinders, T L Th A Jansen*
- 1049** Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis  
*R H Syed, B E Gilliam, T L Moore*
- 1051** Methotrexate and its effect on the anti-GAD titre in two patients with rheumatoid arthritis and diabetes mellitus  
*A W van Deutekom, M T Nurmohamed, M J L Peters, I C van Eijk, B A C Dijkmans, D Hamann, R J Heine, S Simsek*
- 1052** Sex: a major predictor of remission as measured by 28-joint Disease Activity Score (DAS28) in early rheumatoid arthritis?  
*H Mäkinen, P Hannonen, T Sokka*
- 1053** The Glu228Ala polymorphism in the ligand-binding domain of death receptor 4 is not associated with rheumatoid arthritis  
*B Yazdani-Biuki, K Brickmann, U Langsenlehner, W Renner, M Truschmig, P Krippel, F Fürst, W B Graninger, H-P Brezinschek*
- 1054** Reduction of serum interleukin 7 levels upon methotrexate therapy in early rheumatoid arthritis correlates with disease suppression  
*J A G van Roon, K Jacobs, S Verstappen, J Bijlsma, F Lafeber*
- 1055** Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy  
*P Zeni, E Finger, M A Scheinberg*
- 1056** Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma  
*F Mielke, J Schneider-Obermeyer, T Dörner*
- 1057** Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease  
*M Aschwanden, T Daikeler, K A Jaeger, C Thalhammer, A Gratwohl, M Matucci-Cerinic, A Tyndall*
- 1059** Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis  
*K Kitahara, K Takagi, Y Kusunoki, S Nishio, T Nozaki, H Inomata, M Takei, S Sawada, S Kawai*

**Letters**

- 1047** Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease  
*F Lanternier, C Henegar, L Mouthon, P Blanche, L Guillevin, O Launay*
- 1047** Effect of immunoglobulin treatment on endothelial progenitor cells in systemic lupus erythematosus  
*G Coppolino, S Campo, D Bolignano, A Sturiale, M S Giacobbe, S Loddo, M Buemi*



## Take the pain out of research every month

Annals of the Rheumatic Diseases is the premier clinical rheumatology journal in Europe with an impressive impact factor of 5.767, so you'll want the guarantee of reading it every month.

Why not recommend the journal to your librarian or better still, obtain your own personal subscription? You will receive a paper copy every month as well as online access for just £212 a year (€314, \$403). Too much paper on your desk already? An online subscription is just £99 (€147, \$188).

Visit [group.bmj.com/group/subs-sales](http://group.bmj.com/group/subs-sales) - your subscription to this first class journal is just a few clicks away.

[ard.bmj.com](http://ard.bmj.com)

BMJ Journals